[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000188:drug therapy; D002389:Catatonia / Q000188:drug therapy; D002648:Child; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D010259:Paranoid Disorders / Q000188:drug therapy; D011596:Psychomotor Disorders / Q000188:drug therapy*; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy
D006220:Haloperidol
Zur Stellung des Butyrophenon-Derivates Haloperidol in der psychiatrischen Therapie.